Johnson & Johnson · NYSE:JNJ
Johnson & Johnson — Technical Presentation (December 2021)
5 slides from Johnson & Johnson's technical presentation, Dec 16, 2021
Slide 1: Janssen COVID-19 Vaccine
GB-1 Janssen COVID-19 Vaccine Janssen Pharmaceutical Companies of Johnson & Johnson Advisory Committee on Immunization Practices December 16, 2021 Penny Heaton, M.D. Global Therapeutic Area Head, Vaccines, Janssen Research & Development
Slide 2: Month-Over-Month and Kaplan-Meier Plot Demonstrate Good and Durable Vaccine Effectiveness
Month-Over-Month and Kaplan-Meier Plot Demonstrate Good and Durable Vaccine Effectiveness of Single-Dose Vaccine During July-August 2021, When Delta Dominant in US
Slide 3: Benefit-Risk Assessment by Transmission Intensity and Gender: Janssen vaccine vs. no vaccine, Age 18+
Benefit-Risk Assessment by Transmission Intensity and Gender: Janssen vaccine (primary dose) vs. no vaccine, Age 18+ Benefits Transmission Males Females intensity* COVID-19 Low related Medium hospitalizations† High COVID-19 Low related Medium death† High Risks TTS° 2 6 Fatal TTS 0 1 Difference in nu
Slide 4: Phase 3 clinical study showed JNJ booster dose increased protection against symptomatic COVID-19
Phase 3 clinical study showed JNJ booster dose increased protection against symptomatic COVID-19 to 94% in the U.S ENSEMBLE 2 study showed that a booster given ~56 days after primary 12x vaccine provided: • 100 percent protection against severe/critical COVID-19 • 75 percent protection against sympt
Slide 5: Humoral and Cellular Immune Responses after Ad26.COV2.S primary single dose Vaccination
Humoral and Cellular Immune Responses after Ad26.COV2.S primary single dose Vaccination DH Barouch et al. N Engl J Med 2021;385:951-953.
Johnson & Johnson — Technical Presentation (December 2021) on 6ix